These AMCP, AMCP Learn, and Journal of Managed Care & Specialty Pharmacy resources will help advance the role of value-based contracts to improve access and affordability of medications.
These AMCP, AMCP Learn, and Journal of Managed Care + Specialty Pharmacy resources can help increase our understanding of health disparities, their impact, and the role of managed care pharmacy in mitigating them.
The role of digital therapeutics, software that delivers clinical benefits and prevents, manages, and treats medical conditions, has evolved in the past few years. Explore these resources from AMCP, AMCP Learn, and Journal of Managed Care & Specialty Pharmacy resources to learn more about these innovative therapies.
AMCP supports increased access to Prescription Digital Therapeutics (PDTs). PDTs are software-based therapies that deliver clinical benefits to patients, either alone or in combination with other forms of treatment. These therapeutics require a prescription and are subject to oversight by the Food and Drug Administration (FDA). To be approved by the FDA, PDTs must demonstrate both safety and efficacy.
AMCP recognizes that many patients today depend on high‐cost specialty medications that often do not have therapeutic alternatives. Medication cost-share offset programs provide out-of-pocket discounts or free product at the point of sale.
AMCP convened key stakeholders in managed care to address the balance between patient access and payer requirements in the FDA Accelerated Approval (AA) pathway program. Experts from various fields participated, aiming to identify gaps between FDAAA requirements and payer-valued treatment outcomes, explore evidence ecosystem opportunities, and evaluate policy options. The forum emphasized supporting drug development innovation while recognizing payer needs and promoting stakeholder trust in the AA review process. Notably, incentivizing confirmatory trials emerged as a potential impactful policy solution.
The FDA continues to approve novel therapies, but concerns arise due to the costs of certain treatments. To address this, the AMCP organized a forum to explore solutions. Stakeholders recognize the benefits of high-investment medications, but uptake of payment strategies has been slow. Gradual changes, education, and collaboration are essential to improve predictability, affordability, and accessibility for patients.